Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Systemic, Targeted, & Immune Therapies

Add ILCN as a preferred source

September 1, 2016

Alectinib and ALK-Positive Non-Small Cell Lung Cancer – Q&A with Alice T. Shaw, MD, PhD, and Ranee Mehra, MD

Systemic, Targeted, & Immune Therapies

By Erik J. MacLaren, PhD Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that was recently approved in the US as a second- line treatment for ALK-rearranged non-small cell lung cancer (NSCLC) after progression on the standard firstline therapeutic, crizotinib. Data from the J-ALEX trial,1 a Japanese phase 3 study directly comparing first-line efficacy…
June 1, 2016

PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016

Systemic, Targeted, & Immune Therapies

By Erik J. MacLaren, PhD Immunotherapy with anti-PD-L1/PD-1 antibodies is rapidly changing the therapeutic landscape for patients with non-small cell lung cancer (NSCLC). However, selecting the most optimal patient population for those treatments remains a challenge. All pharmaceutical companies with a therapeutic antibody are pursuing a PD-L1 immunohistochemistry (IHC) assay either as a “companion” diagnostic…
April 6, 2016

Afatinib Outperforms Gefitinib in Advanced Non-Small Cell Lung Cancer

Systemic, Targeted, & Immune Therapies

By Erik J. MacLaren, PhD The pan-ErbB inhibitor afatinib (Gilotrif) improves progression-free survival (PFS), time-to-treatment-failure (TTF) rate, and objective response rate (ORR) compared to the first-generation EGFR inhibitor gefitinib (Iressa) as a first-line treatment in patients with EGFR mutation-positive NSCLC, according to results presented at the ESMO Asia 2015 Congress in Singapore.1 Afatinib and gefitinib…
April 1, 2016

Update on Checkpoint Inhibitors in Lung Cancer

Systemic, Targeted, & Immune Therapies

By Erik J. MacLaren, PhD The growing number of checkpoint inhibitors currently being developed, without question, has ushered in a new era in clinical oncology, particularly in the treatment of thoracic malignancies.These agents block various components of the immune checkpoint pathway, such as programmed cell death-1 (PD-1) receptor, which is expressed on the surface of…

Systemic, Targeted, & Immune Therapies

Alectinib and ALK-Positive Non-Small Cell Lung Cancer – Q&A with Alice T. Shaw, MD, PhD, and Ranee Mehra, MD

PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016

Afatinib Outperforms Gefitinib in Advanced Non-Small Cell Lung Cancer

Update on Checkpoint Inhibitors in Lung Cancer

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

No “Known” Risk Factors: The Health Consequences of Radiation Therapy

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

A Holistic Approach to Patient Care